GPC or susceptible anaerobic infectionB. fragilis, Peptostreptococci, non-perfringens clostridial infection0.6-1.2 g IV #2-41.2-2.7 g IV #2-4
Mild or moderate infectionSevere infection150-300 mg PO q6h300-450 mg PO q6h
No renal dose adjustment
Age <1m 16-20 mg/kg IV #3-4
Age 1m-16y 20-40 mg/kg IV #3-4
Mild or moderate infectionSevere infection8-16 mg/kg PO #3-416-20 mg/kg PO #3-4
No renal dose adjustment
Anaerobic infections above the diaphragm, especially dental infection.
Gram-positive skin and soft tissue infections including necrotizing fasciitis as an adjunctive agent to a beta-lactam for reducing toxin production.
Skin & soft tissue infections involving susceptible MRSA.
Susceptible infections and surgical prophylaxis in setting of IgE mediated beta-lactam allergy.
For decreasing toxin production in toxic shock syndrome.
Monitor for diarrhea.
During prolonged therapy, monitor blood count with differential, hepatic and renal functions.
Common
Abdominal pain
Diarrhea
Nausea
Serious
Stevens-Johnson syndrome
Toxic epidermal necrolysis
Erythema multiforme
Clostridium difficile colitis
Agranulocytosis
Antimicrobial class: Lincosamide
Pregnancy category: B
Average serum half life: 2.4 hours
Biliary penetration: Therapeutic
CSF penetration: Poor
Lung penetration: Therapeutic
Urine penetration: Poor
